TEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently received a No-Objection Letter from Health Canada, the country’s primary regulatory authority for drugs and medical products, for the Company’s planned Phase 2 clinical study of NS002, its investigational intranasal epinephrine p ...

Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructureTEL AVIV, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the execution of comprehensive agreements wi ...

合作公告概述 - Nasus Pharma Ltd 与 Aptar France S A S 和 AptarGroup Inc 就NS002项目达成全面合作协议 [1] - 合作旨在支持NS002的临床开发及计划中的商业化 [1] - 此次合作被公司首席执行官视为NS002项目的重大里程碑 [2] 合作战略意义 - 合作使公司获得经过商业验证的Unit Dose System技术及已验证的给药基础设施 [2] - 战略合作关系使公司能受益于成熟的监管路径、生产能力和供应链 [2] - 合作关系将加速NS002的市场化进程并降低开发风险 [2] 合作框架与目标 - 合作建立了全面框架以支持NS002通过美国FDA和欧洲EMA的监管申报 [2] - 公司可获得Aptar的技术专长和生产能力以推进NS002从临床开发到商业化 [2] - 合作进程将与公司的时间表和目标保持一致 [2] 公司技术与产品 - Nasus Pharma是一家临床阶段制药公司专注于开发治疗社区急性医疗状况的鼻内粉末产品 [3] - NS002是公司的鼻内粉末肾上腺素候选产品正被开发作为过敏反应患者肾上腺素自动注射器的无针替代方案 [3] - 公司专有的粉末基鼻内技术旨在实现快速可靠的药物递送利用鼻腔丰富的血管网络进行快速吸收 [3] - PBI配方使用均匀球形粉末颗粒可实现广泛分散且与液体鼻内产品相比可能具有更快更高的吸收率 [3]

A NEW FRONTIER FOR INTRANASAL DRUG DELIVERY Company Presentation – August 2025 A clinical-stage pharmaceutical company leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE American 1 Experienced leadership team Strong IP protection to 2038 Forward Looking Statements This presentation of Nasus Pharma Ltd. contains "forward-looking statements" within the meaning of the Private Securities Litigati ...